Ann: EmtinB Can Become a Revolutionary Treatment for Glaucoma, page-22

(just out from ********* newsletter)

Drug developer NeuroScientific Biopharmaceuticals (ASX: NSB) has revealed the first pre-clinical results of an ophthalmology program that has demonstrated the potential for its lead drug candidate EmtinB to become a “revolutionary” treatment for glaucoma.

EmtinB is a novel therapeutic peptide developed by NeuroScientific that is most advanced as a treatment for Alzheimer’s disease.

In July, the company published results of a “breakthrough study” that showed the drug’s potential to become a “disease-modifying therapy” for Alzheimer’s due to its ability to stimulate the reformation of neuronal network and restore function of injured nerve cells